Hydrochinon Smartpractice Europe (Hydroquinone)

Hydroquinone topical preparations are indicated for a variety of acquired hyperpigmentation conditions that affect visible skin areas.

• Treatment of melasma, a chronic facial pigmentation disorder often linked to hormonal factors.
• Reduction of age spots (solar lentigines) caused by cumulative sun exposure.
• Management of post‑inflammatory hyperpigmentation following skin injury or acne.
• Lightening of freckles, lentigines, and other benign pigmentary lesions.
• Adjunct therapy for hyperpigmentation associated with hormonal changes or medication use.

• Hydroquinone penetrates the epidermis and selectively inhibits the enzyme tyrosinase within melanocytes, which is essential for converting the amino acid tyrosine to melanin. By reducing tyrosinase activity, the drug decreases melanin synthesis and slows the transfer of pigment to surrounding keratinocytes, leading to a gradual lightening of hyperpigmented skin areas.

Adverse reactions to topical hydroquinone are generally dose‑dependent and may vary in severity.

Common

• Mild skin irritation or erythema at the application site.
• Transient dryness or peeling of the treated skin.
• Slight itching or burning sensation during early use.
• Hyperpigmentation rebound if treatment is stopped abruptly.

Serious

• Contact dermatitis with pronounced redness and swelling.
• Exogenous ochronosis, a paradoxical darkening of the skin after prolonged use.
• Rare cases of allergic reactions presenting as urticaria or angioedema.
• Persistent hypopigmentation extending beyond the treated area.

When using Hydroquinone topical products, several safety considerations should be observed.

• Avoid application to broken, inflamed, or infected skin.
• Limit use to the prescribed area and duration; prolonged continuous use may increase risk of ochronosis.
• Protect treated skin from excessive sunlight; use broad‑spectrum sunscreen and protective clothing.
• Discontinue use and seek medical advice if severe irritation or allergic signs develop.
• Pregnant or breastfeeding individuals should consult a healthcare professional before initiating therapy.
• Keep the product out of reach of children and store at room temperature away from moisture.

Hydroquinone may interact with other topical agents or systemic medications that affect skin integrity or melanin production.

Avoid

• Concurrent use of other depigmenting agents such as tretinoin or corticosteroids without medical supervision, as this may increase irritation.
• Application of abrasive exfoliants (e.g., glycolic acid, salicylic acid) on the same area during treatment.

Use with caution

• Combination therapy with retinoids or azelaic acid under dermatologist guidance.
• Use alongside systemic photosensitizing drugs (e.g., tetracyclines) that may heighten sun sensitivity.
• Application of cosmetic products containing fragrances or dyes that could exacerbate dermatitis.
• Use in patients with a history of eczema or atopic dermatitis, monitoring for increased skin reactivity.